Breast

Node Positive (1-3 nodes), HR pos, HER2-neg
  • SWOG S1007: Rx PONDER Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer 

Stage II and III 

  • SWOG ​1207​: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer​
Stage IV

  • CTSU E2108: Early Surgery or Sta​ndard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
  • SWOG 1222:  Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

 

Neo-Adjuvant

 

  • Alliance  A011106:  Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery
  •  NSABP B52:   Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer


  • For more information, contact Cheryl Patz, RN, OCN, CCRC, at 360-788-8238.​​​​